drugset
drugset / Trial / NCT06081465

A Phase I Study of Single and Multiple Doses of VG290131 in Healthy Subjects

NCT06081465 ↗

Phase 1 Recruiting 86 enrolled Zhejiang Vimgreen Pharmaceuticals, Ltd. Tigermed Consulting Co., Ltd · collab
RandomizedSequentialDouble-blindOther

Summary

This is a randomized, double-blind, placebo-controlled phase I study to evaluate the safety, tolerability and PK profiles of orally administered VG290131 in healthy subjects. The main questions it aims to answer are: 1. The safety and tolerability of VG290131 when administered orally as a single dose and multiple doses in healthy subjects. 2. The pharmacokinetic (PK) profiles of VG290131 and the food effect on the PK profiles of VG290131 in healthy subjects. Approximately 86 subjects will be enrolled in the study.

Timeline

Start
2023-10-20
Primary completion
2024-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject VG290131 Unknown 1 mg Oral
Subject VG290131 Unknown 5 mg Oral
Subject VG290131 Unknown 25 mg Oral
Subject VG290131 Unknown 50 mg Oral
Subject VG290131 Unknown 100 mg Oral
Subject VG290131 Unknown 200 mg Oral

Indications

No indication recorded.